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Background: Although the utility of blind biopsy in the detection of metastasis in the carina has
been reported, submucosal fine needle aspiration (SMFNA) has not been evaluated. We inves-
tigated how SMFNA of the main carina and upper-lobe carina in addition to blind biopsy affect
management of patients with NSCLC.
Methods: Thirty-five patients were evaluated. During fiberoptic bronchoscopy (FOB), five blind
biopsy and three SMFNA specimens were collected from normal-appearing main carina
(nZ 35) and/or upper-lobe carina (nZ 18). Subjects were staged for operability using tradi-
tional staging system, without knowing the blind biopsy or SMFNA results. Then, patients were
staged again after results were made known.
Results: Thirty-five NSCLC patients were analyzed. The management of 12 patients (34%) was
changed according to our results. Out of the patients, 8, 5 and one had microscopic metastasis
in the main carina, ipsilateral upper-lobe carina and both, respectively. Although SMFNA were
more diagnostic compared to blind forceps biopsy, there was no statistically difference
between them. These procedures increased the success of detection of microscopic metastasis
and the results changed management of those cases.
Conclusion: SMFNA adds valuable information to blind biopsy, and their combination changed
the management in one quarter of our NSCLC patients.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Surgical excision of tumor provide complete cure in some
patients with non-small cell lung cancer (NSCLC) and is still2 3166333x1129; fax: þ90 442 31
com (E.Y. Ucar).
1 Elsevier Ltd. All rights reservedbest treatment option. However, most of the patients
present with advanced stage tumors at the time of diagnosis
without a chance for surgery. In the patients with NSLC who
are otherwise operable, undetected local or distant66340.
.
1538 H. Kaynar et al.metastatic disease remains a certain possibility despite
a wide variety of staging tools, including invasive procedures
such as mediastinoscopy, mediastinotomy, thoracoscopy,
and even thoracotomy. In addition, in the stage I and II,
predicted five year survival is not as high as it is expected.1
Unnecessary surgical resection and invasive staging
procedures increase medical costs and shorten patient
survival.2,3 Fiberoptic bronchoscopy (FOB), with its low
mortality and morbidity, and high diagnostic yield, is a well-
established tool for diagnosing and preoperatively staging
NSCLC patients.4 FOB allows the bronchoscopist to directly
visualize tumors, perform biopsies and evaluate for tumor
invasion or extension. It can be routinely combined non-
ultrasound guided transbronchial needle aspiration to
sample tumors beneath the mucosa and hilar and medias-
tinal lymphadenopathy detected by computerized tomog-
raphy (CT).5
The value of blind forceps biopsy of the carina in the
staging of lung cancer has been known since 1952.69
Including a recent report by Gu¨nen et al.,10 these studies
show that blind forceps biopsy from the normal-appearing
main carina and upper-lobe carina ipsilateral to the tumor
can provide additional information which may prevent
unnecessary invasive procedures. Although the yield of
transbronchial needle aspiration (TBNA) and forceps biopsy
is similar for visible endobronchial tumors,11 the former
might be more sensitive to detect tumor which is not visible
by endoscopy, but which has infiltrated into the submucosal
and peribronchial tissues.12
Therefore, we prospectively investigated the value of
the addition of blind forceps biopsy and submucosal fine
needle aspiration (SMFNA) results to clinical, radiologic,
and bronchoscopic findings in the management of operable
NSCLC patients with normal-appearing main carina and
ipsilateral upper-lobe carina sites.Materials and methodsPatients
Study protocol was approved by local ethical committee.
Patients presenting to the pulmonary medicine outpatient
clinic with the suspicion of operable lung cancer (as deter-
mined by clinical, spirometric, and chest X-ray and Thorax
CT) who were routinely scheduled for FOB. Forty-two
consecutive patients (mean age 54  9 years; 3 female and
39 male) meeting below criteria were included in the study.
After the initial bronchoscopy, seven patients were excluded
from the study because of the diagnosis of small cell lung
cancer (n Z 3), metastases to the lung from other organs
(n Z 1), and benign processes (n Z 3). Findings from the
remaining thirty-five NSCLC patients were analyzed and
reported. Informed consent of the patients was obtained.Assessment of functional capacity
Patients were included to the study if they had an FEV1 of
2 L or 80% of predicted by spirometry, which was per-
formed at least three days before FOB.13Assessment of radiological operability
All patients were radiologically staged with Postero ante-
rior and lateral chest X-rays, and Thorax CT before the
initial bronchoscopy. We used TNM (T: primary tumor, N:
regional lymph node, M: distant metastasis) classification to
evaluate operability of the patients.14The patients who
were not staged as T4, multistational bulky N2, N3 and M1
were considered radiologically operable and eligible for the
study. Metastasis to a mediastinal lymph node by CT was
considered present if a short axis lymph node diameter of
1 cm on transverse CT section.15
Fiberoptic bronchoscopy
Video-monitorized bronchoscopy (Olympus BF-1T240;
Olympus; Tokyo, Japan) was performed transorally under
local anesthesia in the supine position. FOB was performed
with biopsies and SMFNA by the same person in each patient.
During FOB, the appearance of the carina was described
either as normal, suspicious for tumor invasion, or obvious
tumor invasion. We performed blind forceps biopsy and
SMFNA only in the patients with a normal-appearing main
carina and upper-lobe carina ipsilateral to the tumor at the
initial bronchoscopy only. Patients with any of the following
were suspected of having tumor invasion and not included in
the study: (a) granulation tissue, (b) paleness of mucosa, (c)
thickened, swollen, or deviated tissue, or (d) increased
vascularity. We collected blind forceps biopsy and SMFNA
specimens from the main carina only, or from the main
carina and upper-lobe carina ipsilateral to the tumor. At
least, five blind forceps biopsy (taken deep enough to
include submucosal tissue) and three SMFNA specimens were
collected from each carina. To avoid contamination of tumor
cells, we used separate forceps and needles (Wang 22-gauge
13 mm cytology aspiration needles). Firstly, we performed
blind forceps biopsy and SMFNA from normal-appearing
carina. Then, other procedures such as forceps biopsy,
bronchial lavage, brushing, tarnsbronchial needle aspiration
(TBNA) and transbronchial forceps biopsy (if required) were
performed. To detect possible submucosal tumor infiltra-
tion, the needle was partially introduced at a 45 angle into
the bronchial wall of the carina, and cytologic examination
was considered positive only if large numbers of definitely
malignant cells were present. The presence of ‘atypical cells
only’ and/or ‘abnormal cells highly suggestive of malig-
nancy’ were considered as a negative cytologic examination.
Because, those failed to serve diagnostic endpoints as
described previous studies,16,17 where technical details
regard to fine needle aspiration, specimens handling and
cytopathologic evaluation are available.
Statistical analysis
Fisher’s exact test was used to compare between micro-
scopic metastasis to either carina and histopathological
tumor type, visibility of the tumor on FOB, primary tumor
location and stage of disease. Statistical analysis was per-
formed with SPSS for Windows version 10.0 (SPSS Inc.,
Chicago, USA). Findings were considered statistically
significant if a P value of <0.05 was obtained.
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Thirty-five NSCLC patients were analyzed. Twenty-five of
those who had a visible tumor and two who had no visible
tumor on FOB were diagnosed in the first FOB. Remaining 8
patientswhohadnovisible tumorwerediagnosedeither in the
second bronchoscopy (nZ 2) or via transthoracic fine needle
aspiration (TTFNA) (n Z 5) or thoracotomy (n Z 1) (Fig. 1).
Blind biopsy and SMFNAwere performed from themain carina
and ipsilateral upper-lobe carina of the tumor in 35 and 18
patients, respectively. The procedures did not performed in
the remaining 17 patients who had direct tumoral invasion
(nZ 13) or tumoral invasion suspicion (by visual inspection)
(nZ 4) in the upper-lobe carina. Nomajor complications from
the blind forceps biopsy or SMFNA occurred.
The results of blind forceps biopsy and SMFNA, from the
main carina and ipsilateral upper-lobe carina of the tumor,
according to histopathological tumor type, tumor visuali-
zation on FOB, tumor localization in the upper-lobe, and
clinical stage were summarized in Tables 1 and 2. Although
SMFNA were more diagnostic compared to blind forceps
biopsy, there was no statistically difference between them.
Their difference according to histopathological tumor type,
tumor visualization on FOB, tumor localization in the upper-
lobe, and clinical stage was not statistically significant. The
management of 12 patients (34%) was changed according to
our results. Out of the patients, 8, 5 and one had micro-
scopic metastasis in the main carina, ipsilateral upper-lobe
carina and both, respectively.
As shown Figs. 2 and 3, positive results were obtained via
blind forceps biopsy in 4 and 3 patients, via SMFNA in 6 and
4 patients, and via both procedures in 2 and 2 patients fromFigure 1 Patient flow and diagnostic testing of 35 NSCLC patie
choscopy; TTFNA: transthoracic fine needle aspiration.main carina and ipsilateral upper-lobe carina, respectively.
These procedures increased the success of detection of
microscopic metastasis and the results changed manage-
ment of those cases.
Histopathological findings of the thirty-five patients were
listed in Tables 1 and 2. The histopathological and cytological
diagnosis of blind forceps biopsy and SMFNA was matched
that of primary tumor in all patients. Although positivity of
SMFNA was slightly higher in the cases with squamous cell
carcinoma, there was no significant statistical difference
between blind biopsy and SMFNA positivity according to the
histopathological type.
The primary tumor was visualized on FOB in 25 patients
and not visualized in 10 patients. Although SMFNA positivity
was slightly higher in the cases with visible tumor on FOB,
the rates of positive blind biopsy and SMFNA among patients
with and without directly visible tumor were not statisti-
cally significant different (Tables 1 and 2).Discussion
The results of our study showed that performing blind forceps
biopsy and SMFNA in the cases with lung cancer suspicion and
normal-appearing main carina and ipsilateral upper-lobe
carina has an important effect on the management of
cases. These procedures, in our study, changed the
managementof 12 cases (34%) and saved thepatients froman
unnecessary surgical resection.
Undetected local or distantmetastatic disease in patients
with operable NSCLC remains an important problem, occur-
ring after 10e20% of successful operations, even if widents NSCLC: non-small cell lung cancer; FOB: fiberoptic bron-
Table 1 Lung cancer characteristics, and blind forceps
biopsy and SMFNA results taken from the main carina area in
35 NSCLC patients undergoing staging FOB.
Characteristics Main carina (n Z 35)
Positive
blind biopsy
Positive
SMFNA
Squamous cell carcinoma
(n Z 25)
2 5
Adenocarcinoma (n Z 8) 2 1
Large cell carcinoma (n Z 2) e e
Tumor visualized on FOB
(n Z 25)
2 4
Tumor not visualized on FOB
(n Z 10)
2 2
Tumor location in the UL
(n Z 18)
3 4
Tumor location not in the UL
(n Z 17)
1 2
Stage IA (n Z 4) e e
Stage IB (n Z 3) e e
Stage IIA (n Z 5) e 1
Stage IIB (n Z 16) 2 3
Stage IIIA (n Z 7) 2 2
Note: The staging in this table refers to clinical stage. NSCLC:
non-small cell lung cancer; SMFNA: submucosal fine needle
aspiration; FOB: fiberoptic bronchoscopy; UL: upper-lobe.
Table 2 Lung cancer characteristics, and blind forceps
biopsy and SMFNA results taken from the upper-lobe carina
area ipsilateral to the tumor in 18 of 35 NSCLC patients
undergoing staging FOB.
Characteristics Upper-lobe carina
(n Z 18)
Positive
blind biopsy
Positive
SMFNA
Squamous cell carcinoma
(n Z 11)
2 3
Adenocarcinoma (n Z 5) 1 1
Large cell carcinoma (n Z 2) e e
Tumor visualized on FOB
(n Z 13)
3 4
Tumor not visualized on FOB
(n Z 5)
e e
Tumor location in the UL
(n Z 10)
2 2
Tumor location not in the UL
(n Z 8)
1 2
Stage IA (n Z 4) 1 2
Stage IB (n Z 1) e e
Stage IIA (n Z 4) 1 1
Stage IIB (n Z 7) e e
Stage IIIA (n Z 2) 1 1
Note: The staging in this table refers to clinical stage. NSCLC:
non-small cell lung cancer; SMFNA: submucosal fine needle
aspiration; FOB: fiberoptic bronchoscopy; UL: upper-lobe.
1540 H. Kaynar et al.negative excisional margins were obtained on histopatho-
logical examination.18,19 Researchers have suggested that
tumor spread occurs mainly via submucosal lymphatics, and
in the mucosal and outer fibrous layers of bronchus.20,21
Thus, sampling of mucosa and submucosa, even the
mucosal surfaces have normal appearance during FOB,
should be done. Our results were favor of use of blind forceps
biopsy and SMFNA in those cases. Because the number of
cases detected microscopic metastasis were considerable.
To achieve complete cure and avoid postoperative residual
tumor after the surgery, the main carina should be evaluated
carefully and it should be histopathologically free of
tumor.22,23 In the previous studies, using either rigid or fiber-
optic bronchoscopes, histopathologic evidence of tumor
dissemination at themain carina have been reported between
4.7 and 13.7% byblind forceps biopsy.6e10 The authors of these
studies concluded that blind forceps biopsy was a simple, low-
risk, inexpensive procedure which save many patients from
unnecessary surgery and invasive staging techniques which
carry a high risk of morbidity and mortality. We thought,
however, that blind forceps biopsy alone was inadequate to
detect microscopic metastasis at these sites, and that the
addition of SMFNA would be useful. Indeed, SMFNA has been
shown to be more sensitive than forceps biopsy for detecting
tumor cells infiltrating the submucosal and peribronchial
tissues.12,15,16 We also found SMFNA to be more sensitive than
blind forceps biopsy in tumors infiltrating the submucosal
layers, andadding this to blind forcepsbiopsy changed surgical
planning for almost one quarter of our NSCLC patients.Our rate (11.4%) of positive blind forceps biopsy of the
main carina was similar to some of previous studies which
used a rigid bronchoscope or FOB.6,9,10 Other studies using
a FOB, however, reported lower rates (6% and 4.7%) of posi-
tive blind biopsy of main carina.7,8 It is unclear but they may
have taken an inadequate number of forceps biopsy samples.
Although some authors have suggested an optimal number of
biopsies for diagnosing of directly-observable bronchogenic
carcinoma via FOB,24 no study to date has examined the
adequate number needed to detect microscopic metastasis.
Some recent guidelines have no such recommendation for
either the procedure of choice or the number of biopsy from
the mucosa of main carina with normal appearance.5,25 So,
we decided upon collecting at least five specimens of blind
forceps biopsy from themain carina, and, the bronchoscopist
was careful to obtain biopsy specimens deep enough to
include submucosal tissue. We foundmicroscopic metastasis
in the main carina in four of 10 patients with non-visualized
tumors. Our higher rate than that of the study by Gu¨nen
et al. may be explained our use of SMFNA in addition to blind
forceps biopsy. In the upper-lobe carina area, we found
a lower rate (16.7%) of microscopic metastasis than that of
the study by Gu¨nen et al.10 (23.5%), but we excluded the
cases with multistational bulky N2 disease and it is unclear
whether they included or not such patients.
Therewere some limitations for our study. Firstly,wewere
not able to confirm metastatic disease at histopathological
Figure 2 Microscopic metastasis to main carina by blind
forceps biopsy (circle A) in four patients (11.4%) and by SMFNA
(circle B) in 6 (17.1%) of 35 patients. Both tests were positive in
two patients, thus eight (22.9%) of 35 patients had microscopic
metastasis diagnosed at the main carina. SMFNA: submucosal
fine needle aspiration.
Detection of microscopic metastasis of carina 1541examination of surgical specimens in the upper-lobe carina of
four patients because they either refused surgery or their
surgery was not performed in our center. Secondly, bron-
choscopy always carries a small risk of contamination, andwe
used separate forceps and needles to obtain blind biopsy and
SMFNA specimens from each carina to minimize this possi-
bility. A third limitation of our study was that it was not
controlled, that is, all patients underwent the same sampling
procedures. A fourth limitation may be our use of WangFigure 3 Microscopic metastasis to the ipsilateral upper-lobe
carina by blind forceps biopsy (circle A) in three patients
(16.7%) and by SMFNA (circle B) in four (22.2%) of 18 patients.
Both tests were positive in two patients, thus five (27.8%) of 18
patients had microscopic metastasis diagnosed at upper-lobe
carina ipsilateral to the tumor. SMFNA: submucosal fine nee-
dle aspiration.22-gauge cytology aspiration needles for SMFNA. Although it
has been reported that use of that needle has been useful in
the staging and diagnosis of bronchogenic carcinoma,26,27 but
larger caliber (18 or 19 gauge) histology needles may likely
have possibility to increase success rates. Those needles have
used for TBNA in mediastinal staging and diagnosis of lung
cancer and have been reported to increase the yield over that
of 21- or 22-gauge needles.28,29 Although histology and
cytology needles have been compared for their ability to
accurately sample tissues frommediastinalmasses, todateno
studies but one, according to our best knowledge, have
compared their yields for tumors infiltrating into submucosal
or peribronchial tissues.30 However, in that study, the author
did not find any statistical difference in the diagnostic rate of
sampling of endobronchial lesions with both calibers needles.
Thus,useof22-gaugeneedledoesnot seemnottobeplausible
in such situations.
In conclusion, SMFNA of the main carina and upper-lobe
carina, in addition to blind forceps biopsy, should be per-
formed upon initial FOB in order to complement other
methods of diagnosing bronchogenic carcinoma. Cytological,
as well as histological, analysis of such key anatomic sites can
have impact on the planning of further staging and curative
procedures. Their use may save a considerable number of
patients from unnecessary staging interventions and surgery
which have increased costs and risks.
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